ELN. LIMS. QMS. When it comes to lab data, there are a lot of three to four-letter acronyms. For many people, an ELN, shorthand for an electronic lab notebook, is arguably the most important. In fact, at Ganymede, many of the biotech companies we talk with view their ELN as
Imagine the lab of the future. Scientists are able to seamlessly conduct experiments across multiple instruments. With a few clicks, they generate amazing charts and uncover valuable insights. Everything flows smoothly and efficiently. And with that efficiency comes more time in scientists’ days. Time to think, discover, and collaborate. That’
We’re excited to share the first post in our new Mission Logs series, a set of Q&A style blog posts with industry leaders, thinkers, and doers. Today, we’re showcasing a conversation with David Dambman, a true expert in automation, both in terms of robotics and data.
The New Year is here, and many folks in biotech are probably ready to say goodbye to 2023. Coming out of the pandemic, the last few years haven’t been easy on the life science industry. We’ve seen layoffs, waning funding from VCs, and a drop in biotech IPOs.
On the surface, the life science and finance industries don’t appear to have much in common. Biotech conjures up visions of beakers and petri dishes, while finance evokes an image of endless spreadsheets, stock tickers, and office cubicles. However, there are actually more similarities between these industries than people